Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
65 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-18 |
Cash Flow (TTM) (Millions $) |
-8 |
Capital Exp. (TTM) (Millions $) |
0 |
Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine, Inc. is a biotechnology company that focuses on the development and commercialization of precision medicine therapies for the treatment of neurological and psychiatric disorders. The company utilizes a precision medicine approach by identifying genetic variations and biomarkers in order to develop targeted therapies that address the underlying genetic causes of these disorders. Aevi Genomic Medicine aims to improve patient outcomes by providing personalized treatments that are more effective and have fewer side effects compared to traditional approaches. The company's research and development efforts focus on a variety of neurological and psychiatric conditions, including attention deficit hyperactivity disorder (ADHD) and schizophrenia.
|